Actively Recruiting

Age: 18Years +
All Genders
NCT07237516

Zymfentra (Infliximab-dyyb) REal World Cohort STudy

Led by University of North Carolina, Chapel Hill · Updated on 2026-03-17

200

Participants Needed

5

Research Sites

154 weeks

Total Duration

On this page

Sponsors

U

University of North Carolina, Chapel Hill

Lead Sponsor

C

Celltrion

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this observational study is to learn about how effective Zymfentra (IFX=dyyb) is when treating patients with Crohn's disease (CD) and ulcerative colitis (UC) Does Zymfentra lead to a reduction in symptoms at intervals throughout one year? Participants being prescribed Zymfentra (IFX-dyyb as part of their regular medical care for CD or UC will answer online survey questions about their bowel habits for 1 year.

CONDITIONS

Official Title

Zymfentra (Infliximab-dyyb) REal World Cohort STudy

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adult patients age 18 years or older with Crohn's disease, ulcerative colitis, or Inflammatory Bowel Disease Unclassified
  • Starting Zymfentra at week 10 following standard intravenous induction therapy at weeks 0, 2, and 6, or switching from infliximab originator or biosimilars during maintenance to Zymfentra
  • Expected to be followed by the participating center for 12 months
  • Diagnosis based on standard clinical, radiographic, endoscopic, and histologic criteria including symptoms such as diarrhea, rectal bleeding, abdominal pain, fever, complicated perianal disease, extraintestinal manifestations, weight loss, or failure to thrive
  • Symptoms present on two or more occasions separated by at least 8 weeks or ongoing symptoms for at least 6 weeks
  • Objective evidence of inflammation by endoscopy, radiology, or histology as specified in the study guidelines
  • Classification into Crohn's disease, ulcerative colitis, or Inflammatory Bowel Disease Unclassified based on detailed diagnostic criteria
Not Eligible

You will not qualify if you...

  • Unable to provide informed consent
  • Non-English speaking
  • Patients presenting for a one-time consultation only

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

University of Iowa

Iowa City, Iowa, United States, 52242

Actively Recruiting

2

Mercy Medical Center

Baltimore, Maryland, United States, 21202

Actively Recruiting

3

Brigham and Women's Hospital

Boston, Massachusetts, United States, 02115

Actively Recruiting

4

New York University

New York, New York, United States, 10016

Actively Recruiting

5

University of North Carolina

Chapel Hill, North Carolina, United States, 27599-7080

Actively Recruiting

Loading map...

Research Team

S

Susan Jackson

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here